Tradjenta FDA Approved Drugs
TRADJENTA [LinagliptinC25H28N8O2]
RX
- 5mg (oral tablet)
Boehringer IngelheimMay 2, 2011
- Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone.
- Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonlyurea.
- Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.
- Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidaste-iv inhibitor.
- Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone).
- Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin.
- Method of treating type 2 diabetes mellitus by administering linagliptin.
- Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin.
- Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin.
- Treatment of type 2 diabetes mellitus.
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.